Article: Study designed to discover the genomic marker for patients at risk of clozapine-induced agranulocytosis.

2002 MAY 24 - (NewsRx.com & NewsRx.net) -- Genaissance Pharmaceuticals, Inc., (GNSC), announced that the first patient was enrolled in its clinical study designed to discover the genomic marker(s) for identifying patients at risk of clozapine-induced agranulocytosis, a potentially life-threatening depletion of white blood cells.

The CARING (Clozapine and Agranulocytosis Relationships Investigated by Genetics (HAP Markers)) Study is the first study in the company's HAP-Clozapine development plan, and is designed to provide the information that may ultimately enable physicians to prescribe HAP-Clozapine to patients while minimizing or eliminating the need for the ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!